Results 181 to 190 of about 215,861 (352)

Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response. [PDF]

Hypertension
Theken KN, Ghosh S, Skarke C, Fries S, Lahens NF, Sarantopoulou D, Grant GR, FitzGerald GA, Grosser T.   +8 more
europepmc   +1 more source

Supplementary Methods, Figures 1-6 from Selective Visualization of Cyclooxygenase-2 in Inflammation and Cancer by Targeted Fluorescent Imaging Agents

, 2023
Md. Jashim Uddin, Brenda C. Crews, Anna L. Blobaum, Philip J. Kingsley, D. Lee Gorden, J. Oliver McIntyre, Lynn M. Matrisian, Kotha Subbaramaiah, Andrew J. Dannenberg, David W. Piston, Lawrence J. Marnett   +10 more
openalex   +1 more source

Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies

Advanced Healthcare Materials, EarlyView.
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best, Gizem Karabiyik, Gerd Geerling, Sarah Barbara Zwingelberg, Gregor Lang, Martin Humenik   +5 more
wiley   +1 more source

Radioiodination of Two Carborane-Based Dual Cyclooxygenase-2/5-Lipoxygenase Inhibitors and Their In Vitro and In Vivo Evaluation. [PDF]

Chembiochem
Schädlich J, Ullrich M, Haase-Kohn C, Wodtke R, Braun S, Molitor M, Hofmann B, Steinhilber D, Kopka K, Hey-Hawkins E, Pietzsch J, Laube M.   +11 more
europepmc   +1 more source

Synthesis of E-stilbens as Potent Cyclooxygenase-2 Inhibitors and Identification of their Photochemical Products [PDF]

, 2014
Ahmadreza Bekhradnia, Maryam Ahmadian Moghadam, Monire Tatar   +2 more
openalex  

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Cyclooxygenase-2 (COX-2) as a Potential Prognostic Marker in Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. [PDF]

Health Sci Rep
Qasem HM, Odat RM, Alshwayyat S, Younis OM, Yasin JA, Hussein AM, Hammadeh BM, Ghlailat M, Amayreh LA, Yadav R, Nguyen D, Jain H, Kelkar R.   +12 more
europepmc   +1 more source

Bombesin induced cyclooxygenase-2 expression and differentiation in intestinal epithelial cells

, 2000
Yan-Shi Guo, Xiaodong Wen, Courtney M. Townsend, Mark R. Hellmich   +3 more
openalex   +1 more source

In Vitro Cyclooxygenase-2 Protein Expression and Enzymatic Activity in Neoplastic Cells [PDF]

, 2007
David Heller, Timothy M. Fan, Louis‐Philippe de Lorimier, Sarah C. Charney, Anne M. Barger, Sarah H. Tannehill‐Gregg, Thomas J. Rosol, Matthew A. Wallig   +7 more
openalex   +1 more source

Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury

Advanced Healthcare Materials, EarlyView.
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang, Wing Yan Chung, Serena M. Pulente, Yubin Lei, Khang Nguyen, Eddie Tam, Nadya M. Morrow, Ilka Lorenzen‐Schmidt, Fengxia Xiao, Augusto Zani, Dylan Burger, Hye Kyoung Sung, Erin E. Mulvihill, Gary Sweeney   +13 more
wiley   +1 more source